TILDRAKIZUMAB VERSUS GUSELKUMAB: A BUCHER INDIRECT COMPARISON

被引：0
|
作者：
Du Jardin, Gaarn K. [1 ]
Hurtado, P. [2 ]
Lange, M. [1 ]
McCool, R. [3 ]
Maeso Naval, S. [2 ]
Quickert, S. [4 ]
机构：
[1] Almirall Nord, Copenhague, Denmark
[2] Almirall SA, Barcelona, Spain
[3] York Hlth Econ Consortium Ltd, York, N Yorkshire, England
[4] Quant Biostat, Edinburgh, Midlothian, Scotland
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDG4
引用
收藏
页码：S597 / S597
页数：1
相关论文
共 50 条
  • [1] Indirect comparison of ixekizumab versus guselkumab up to week 12
    Gottlieb, A.
    Ramot, Y.
    Smith, S.
    Saure, D.
    Schacht, A.
    Dossenbach, M.
    Wilhelm, S.
    Thaci, D.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 90 - 90
  • [2] Indirect comparison of Ixekizumab versus Guselkumab up to week 12
    Gottlieb, A. B.
    Ramot, Y.
    Smith, S. D.
    Saure, D.
    Schacht, A.
    Dossenbach, M.
    Wilhelm, S.
    Thaci, D.
    Eppendorfer, S.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 120 - 120
  • [3] Indirect comparison of ixekizumab versus guselkumab up to week 12
    Gottlieb, A.
    Ramot, Y.
    Smith, S.
    Saure, D.
    Schacht, A.
    Dossenbach, M.
    Wilhelm, S.
    Thaci, D.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (05) : S3 - S3
  • [4] COMPARATIVE EFFICACY OF GUSELKUMAB AND TILDRAKIZUMAB IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: A MATCHING-ADJUSTED INDIRECT COMPARISON
    Van, Sanden S.
    Diels, J.
    Schubert, A.
    Barthelmes, J.
    [J]. VALUE IN HEALTH, 2020, 23 : S410 - S410
  • [5] Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study
    Megna, Matteo
    Tommasino, Nello
    Potestio, Luca
    Battista, Teresa
    Ruggiero, Angelo
    Noto, Matteo
    Fabbrocini, Gabriella
    Genco, Lucia
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (06) : 2813 - 2820
  • [6] Indirect comparison of ixekizumab versus tildrakizumab for up to 12 weeks of treatment in patients with moderate-to-severe psoriasis
    Gottlieb, Alice
    Saure, Daniel
    Wilhelm, Stefan
    Dossenbach, Martin
    Thaci, Diamant
    Smith, Saxon D.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB82 - AB82
  • [7] Successful therapy of psoriasis with risankizumab after previous failure of guselkumab and tildrakizumab
    Kromer, Christian
    Mohr, Johannes
    Schoen, Michael Peter
    Moessner, Rotraut
    [J]. DERMATOLOGIC THERAPY, 2020, 33 (06)
  • [8] A successful switch from guselkumab to tildrakizumab during the treatment of a patient with psoriasis vulgaris
    Yatsuzuka, Kazuki
    Murakami, Masamoto
    [J]. JOURNAL OF CUTANEOUS IMMUNOLOGY AND ALLERGY, 2023, 6 (03) : 98 - 99
  • [9] Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
    Ruggiero, Angelo
    Picone, Vincenzo
    Martora, Fabrizio
    Fabbrocini, Gabriella
    Megna, Matteo
    [J]. CLINICAL COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 2022, 15 : 1649 - 1658
  • [10] Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison
    Ruggiero, Angelo
    Fabbrocini, Gabriella
    Cinelli, Eleonora
    Megna, Matteo
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (04) : 1028 - 1030
12345